Celgene Returns To Forma’s Door, This Time With Option To Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
The big biotech signed an expansive collaboration with the drug discovery company spanning multiple targets and numerous therapeutic areas. Celgene agreed to pay $225 million upfront and could eventually buy the company.
You may also be interested in...
Third Rock Launches Nurix With Ambitions Of Next-Gen Velcade
The recently uncovered biotech a la Third Rock and The Column Group is focused on the ubiquitin protease pathway and its applications in oncology.
Deals Of The Week Examines How Amarin Reeled In A Partner For Vascepa
Amarin signed Kowa Pharmaceuticals America as a commercial partner for its fish oil pill, more than doubling the number of sales reps detailing the medicine. Forma signed a second drug discovery pact with Celgene, while Baxter bolstered its hemophilia franchise by buying out partner Chatham Therapeutics.
Forma To Rev Its Discovery Engine For Deubiquitination
In a new collaboration with Cancer Research Technology, drug-discovery firm Forma Therapeutics adds another area of cancer biology – and another unusual deal structure – to its panoply of partnerships.